CEDAR KNOLLS, NJ--(Marketwired - May 13, 2014) - MYOS Corporation ("MYOS" or the "Company") (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that the Company is a platinum sponsor of the 2nd Cancer Cachexia Conference: Evolving Mechanisms and Therapies ("Cancer Cachexia 2014") being held September 26-28, 2014 in Montreal, Canada. The Cancer Cachexia 2014 scientific program will focus on clinical manifestations of cachexia in cancer patients, the molecular mechanisms leading to weight loss, fatigue and wasting in cancer patients, the relationship between cancer and other atrophy conditions, and the discovery of new therapeutic strategies for the treatment of disease-related muscle wasting.

"We believe that through prevention or reversal of muscle loss associated with cancer, patients may benefit from significantly improved treatment outcomes measured by both increased survival and enhanced quality of life. MYOS is committed to our ongoing research supporting the development of safe and effective treatment options addressing the critical need to maintain and increase healthy muscle mass in patients suffering from the serious debilitating and often life-threatening effects of cancer cachexia," said Robert Ashton, M.D., MYOS' Chief Medical Officer. "We are pleased to support the Cancer Cachexia 2014 conference as it serves as an important forum for world-renowned experts focused on cachexia and muscle wasting to broaden the discussion around current effective treatments and identify the best therapeutic options for patients."

Cancer cachexia is a serious, complex wasting syndrome common in patients with cancer defined by an ongoing loss of adipose and skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional and metabolic dysfunction characterized by weakness and fatigue. Current data indicate that more than half of all cancer patients show evidence of the cachexia syndrome, leading to substantial impairment of respiratory muscle function and contributing to poor quality of life and decreased survival. Cachexia results in significant weight loss in a person who is not actively trying to lose weight and is usually accompanied by muscle atrophy, weakness, fatigue and loss of appetite. Additionally, cachexia is a very serious complication in a variety of other serious diseases such as HIV, chronic obstructive pulmonary disease (COPD), multiple sclerosis, chronic kidney disease and congestive heart failure.

About Cancer Cachexia 2014
The 2nd Conference on Cancer Cachexia: Evolving Mechanism and Therapies is organized under the auspices of the McGill University Goodman Cancer Centre, The Ohio State University Comprehensive Cancer Center and the University of Vermont College of Medicine along with Society on Sarcopenia, Cachexia and Wasting Disorders. For more information on Cancer Cachexia 2014 please visit www.cancercachexia2014.com and for additional information regarding Cancer Cachexia please visit www.cancercachexia.com.

About MYOS Corporation
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin (also known as MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

The Company's first commercial product MYO-X™, powered by MYO-T12®, is distributed by Maximum Human Performance (MHP) and is currently available on popular retailer websites including www.mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that MYO-X, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of MYO-T12® and its effects on myostatin inhibition, including our research and development activities described herein or in our other public filings, product and customer demand, the continued growth of repeat purchases, market acceptance of our products, the ability to create new products through research and development, the continued growth in market expansion and revenue, the successful entry into new markets, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of MYO-X™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact Information:

Investor and Media Contact:
Jenene Thomas
Investor Relations and Corporate Communications
(973) 509-0444